Projects per year
Expertise & Capabilities
I am an interdisciplinary pharmaceutical researcher with experience in developing injectable drugs (antibodies, small molecules, and nanomedicines). I have significant expertise in the analytical characterization of critical quality attributes for these products and the design of pre-clinical studies for evaluating biological performance (biopharmaceutics).
My laboratory hosts a Malvern Panalytical NanoSight NS300 and Archimedes Resonant Mass Measurement, which are both used to measure particle size and concentration. If you would be interested in accessing these technologies, please get in touch (firstname.lastname@example.org).
I am also Director for the new EPSRC Multiscale Metrology Suite (modular setup including Field Flow Fractionation, Inductively-coupled mass spectrometry, Light Scattering and Raman) for Next-Generation Health Nanotechnologies (EP/V028960/1). For more information or to access this facility, please get in touch.
Senior Lecturer in Translational Pharmaceutics
I am a pharmacist by training with experience of working within the hospital, community and industry sectors. I have contributed to a diverse molecule portfolio spanning pre-clinical to late-stage development during my time at AstraZeneca and in collaboration with Patrys Ltd at the Yale School of Medicine (PAT-DX1).
My research team has two overall interests;
i) Analytical characterization of parenteral formulation attributes and in vivo performance:
A key challenge in the commercial translation of newly-discovered drugs is understanding the key performance indicating characteristics crucial to their biological performance and how they interact with living systems. We are interested in developing new tools to profile these performance characteristics.
Areas of research interest in my lab are summarized as follows;
- Understanding the environmental and physicochemical determinants of solution-phase formulation stability for antibody and suspension formulations.
- Determining key critical quality attributes in particle design to inform optimal in vivo performance.
- Analytical evaluation of nanomedicine interaction with biological media, and the mechanism of cellular uptake in two- and three-dimensional cellular models. We use the latest in field flow fractionation and orthogonal analytical techniques to probe the interaction between nanomaterials and biofluids. Knowledge of particle parameters altering the biological performance of nanomedicines, can be used to reverse engineer novel biocompatible prototypes.
- Applying novel imaging modalities for evaluating drug and nanoparticle biodistribution, and impact on tumor response.
- The interplay between the tumour microenvironment and nanomedicine in vivo performance with a view to developing biorelevant in vitro tests.
ii) DNA repair agents and the nuclear import pathway, and their role in cancer:
We are interested in screening the functional and phenotypic role of DNA repair mutations. We also develop new small molecule drugs against various nuclear import transporters known to be elevated in cancer. In the fight against cancer, we want to contribute to the discovery of new lifesaving drug treatments.
Public Engagement & Outreach
When not in the lab, I am passionate about improving access to education, achievement and realizing potential for young budding scientists and am open to local STEM and healthcare-related widening participation initiatives. Without the next-generation of scientists and researchers, all the developments made in science to-date would be in vain.
I am co-director (Pharmacy) with Dr Margaret Cunningham (Biomedical Sciences) for outreach in the Strathclyde Institute of Pharmacy & Biomedical Sciences.
Recently I became an elected member of the RSE Young Academy of Scotland, where I am the lead for communications. I am the Chair of the Academy of Pharmaceutical Science Advanced Therapy Medicinal Products focus group which was launched in fall 2020. I am review editor for the Frontiers in Endocrinology Journal (2019-present) and a newly-appointed associate EPSRC peer review college member (2021-present).
I am passionate about equity in STEMM and actively seek opportunities to champion scientists from a diversity of backgrounds. If you want to join the Rattray Laboratory of Complex Bioanalysis as a visiting scholar, PhD researcher or fellow please do get in touch!
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
University Of Strathclyde
Award Date: 1 Jul 2021
Master of Pharmacy, University of Manchester
Sep 2004 → May 2008
Award Date: 8 Jul 2008
Doctor of Philosophy
Sep 2009 → May 2013
- Drug Delivery
- Drug development
- Protein aggregation
- Cancer therapy
- 1 Similar Profiles
Dive into details
Select a country/territory to view shared publications and projects
1/08/21 → 31/07/24
SPRINT: A SuPer-Resolution time-resolved ImagiNg and specTroscopy facility for rapid biomolecular analysis
1/07/21 → 30/06/22
Cai, Y., Rattray, N. J. W., Zhang, Q., Mironova, V., Santos-Neto, A., Hsu, K-S., Rattray, Z., Cross, J. R., Zhang, Y., Paty, P. B., Khan, S. A. & Johnson, C. H., 17 Mar 2020, In: Scientific Reports. 10, 13 p., 4905.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile
ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibodyRattray, Z., Deng, G., Zhang, S., Shirali, A., May, C. K., Chen, X., Cuffari, B. J., Liu, J., Zou, P., Rattray, N. J. W., Johnson, C. H., Dubljevic, V., Campbell, J. A., Huttner, A., Baehring, J. M., Zhou, J. & Hansen, J. E., 22 Jul 2021, In: JCI Insight. 6, 14, 39 p., e145875.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile5 Downloads (Pure)
Zahra Rattray (Chair)Apr 2021 → …
Activity: Membership types › Membership of committee
Strathclyde Institute Of Pharmacy And Biomedical Sciences